AlphAIAlphAI — Financial news for AI agents
rttnews.comSEP 82 min read$PDSB

PDS Biotech Raises Up To $22.55M In PIPE Led By Dr. Patrick Soon-Shiong

PDS Biotech (PDSB) raised up to $22.55M in a PIPE transaction led by Nant Capital. The financing includes an initial $11.55M closing and a $11M milestone closing tied to FDA submission. Proceeds will support PDS0301's late-stage development. PDSB stock is up 29.70%.

Original reporting
rttnews.com
Published Sep 8, 2026, 4:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 8, 2026, 4:34 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefCorporate actions
Primary signal
$PDSB
Bullish
high confidence
Mentioned
$PDSB
Relevance
8/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$PDSBBullishHigh
01

Why it matters

The PIPE financing secures needed capital for advancing PDS0301, while interim Phase 2 results show promising survival outcomes, likely prompting investor interest.

02

Market read

The financing and trial data provide fresh catalysts for PDSB, potentially driving short‑term price appreciation and influencing peer biotech sentiment.

03

What to watch

Potential regulatory delays for the Phase 3 filing and execution risk of milestone payments.

Relevance 8/10Novelty 8/10Timing: initial closing expected Sep 11 2026

Background

PDS Biotech is a clinical‑stage company developing IL‑12 immunocytokine therapies for solid tumors.

Company-level read

Ticker impact

$PDSBBullishHigh confidence
Context

PDS Biotech announced a PIPE financing of up to $22.55 million, with an initial $11.55 million closing expected around Sep 11 2026.

Expected impact

Potential short‑term upside of 10‑15% if the financing proceeds and Phase 3 filing are confirmed.

Evidence & confidence

New financing and positive Phase 2 data are fresh catalysts for a micro‑cap biotech, likely attracting speculative buying.

Market effects

Sector

Adds momentum to the oncology immunotherapy sector as a peer secures significant funding.

Regional

May lift other US‑listed biotech stocks in the near term.

Global

Limited to biotech investors; unlikely to affect broader indices.

Counterpoint

What could challenge this read

The modest raise size and dilution risk could outweigh short‑term hype, leading to price pressure.

Key entities

  • company
    PDS Biotechnology Corporation

    US‑listed biotech (NASDAQ:PDSB) developing targeted immunotherapies.

  • investor
    Nant Capital, LLC

    Lead investor in the PIPE transaction.

  • individual
    Dr. Patrick Soon‑Shiong

    Founder of NantWorks and designated board member of PDSB.

Read at source← All news

Also covered by

1 outlet

Related articles

SEP 8
$BJDXMedAI 8/10

5 Biotech Stocks To Watch: Bluejay, Pharvaris, Roivant, PDSB & Atara

Bluejay Diagnostics (BJDX) partnered with Lovell Government Services for federal healthcare market access, trading at $1.05, up 27.4%. Pharvaris (PHVS) reported 83% attack rate reduction in HAE study, trading at $37.82, up 7.02%. Roivant (ROIV) showed positive Phase 2 results for mosliciguat, trading at $41.35, up 18.35%. Atara Biotherapeutics (ATRA) updated BLA resubmission plans, trading at $10.71, up 9.73%. PDS Biotech (PDSB) raised $22.55M in PIPE financing, trading at $0.29, up 33.21%.

rttnews.com3 min
SEP 8
$PDSBHighAI 8/10

80% survived at least two years in a 22-patient trial of PDS Biotech's cancer treatment

PDS Biotech (PDSB) secured a PIPE financing of up to $22.55M led by Nant Capital, with an initial closing of $11.55M expected by September 11, 2026. The funds will support late-stage development of PDS0301, following Phase 2 trial data showing 80% 24-month survival in 22 metastatic colorectal cancer patients. Nant Capital may designate two board members, including Dr. Patrick Soon-Shiong, while owning at least 15% of the common stock.

stocktitan.net2 min
AUG 19
$PDSBLow

PDS Biotechnology (NASDAQ: PDSB) CEO takes interim finance role as CFO departs

PDS Biotechnology (PDSB) announced CFO Lars Boesgaard's resignation effective September 12, 2026. CEO Frank Bedu-Addo will serve as interim Principal Financial Officer, while Janetta Trochimiuk becomes interim Principal Accounting Officer with a $279,519.57 annual salary. Boesgaard's departure is not due to disagreements. Trochimiuk remains eligible for future equity awards.

stocktitan.net1 min
AUG 13
$PDSBHighAI 8/10

PDS Biotechnology (PDSB) cuts R&D spend but warns on going concern, cash at $5.6M

PDS Biotechnology (PDSB) reported a $17.1M net loss for the six months ended June 30, 2026, with no product revenue. Operating expenses fell to $13.0M from $16.7M. Cash dropped to $5.6M from $26.7M at year-end 2025, and management said there is substantial doubt about its going concern. In June 2026, it redeemed $22.2M convertible debentures and issued a $6.0M 10% promissory note.

stocktitan.net6 min
AUG 13
$PDSBMed

PDS Biotechnology Corp (PDSB): Results of Operations and Financial Condition

PDS Biotechnology Corp (PDSB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 PDS Biotech Reports Second Quarter 2026 Financial Results PRINCETON, N.J., August 13, 2026 -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a clinical-stage biotechnology company focused on developing targeted immunotherapies for canc

SEC EDGAR 8-K6 min